AnaptysBio, Inc. (ANAB)

Pharmaceutical Preparations · market cap $1.5B · as of 2026-07-17

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-11-03 (est.)

Earnings

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

AnaptysBio (ANAB) is a clinical-stage pharmaceutical company with ~136 employees and a $1.6B market cap, centered on two Phase 2 assets: rosnilimab (rheumatoid arthritis) and etokimab (chronic rhinosinusitis). The company carries $248.5M in cash (~29 months of runway) and no debt, with no near-term binary readouts beyond an August 5, 2026 earnings call.

The catalyst path

2026-11-03 (est.)Earningsimp 5/10

Pipeline

Asset	Phase	Indication
Rosnilimab	Phase 2	Rheumatoid Arthritis
Etokimab	Phase 2	Chronic Rhinosinusitis

Price & technical context

3-month

-23.3%

6-month

+28.6%

12-month

+138.3%

52-wk range

$19.91–$69.81

vs 50-day MA

-11.8%

vs 200-day MA

-0.2%

Realized vol

62.3%

Max drawdown

-69.2%

Daily closes through 2026-10-01. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

Sources & data

SEC filings — EDGAR filings for ANAB (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 2 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.